이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IDEXX Laboratories 미래 성장

Future 기준 확인 3/6

IDEXX Laboratories (는) 각각 연간 9.9% 및 8.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 35.6% 로 예상됩니다.

주요 정보

9.9%

수익 성장률

11.1%

EPS 성장률

Medical Equipment 수익 성장	0%
매출 성장률	8.7%
향후 자기자본 수익률	35.6%
애널리스트 커버리지	Good
마지막 업데이트	23 Jun 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

BMV:IDXX * - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	4,777	1,167	1,068	1,226	9
12/31/2025	4,339	1,036	983	1,106	11
12/31/2024	3,944	922	885	1,097	11
3/31/2024	3,725	867	797	921	N/A
12/31/2023	3,661	845	773	907	N/A
9/30/2023	3,588	823	680	830	N/A
6/30/2023	3,514	791	593	747	N/A
3/31/2023	3,431	699	456	612	N/A
12/31/2022	3,367	679	384	543	N/A
9/30/2022	3,340	670	438	580	N/A
6/30/2022	3,309	664	429	578	N/A
3/31/2022	3,274	735	605	746	N/A
12/31/2021	3,215	745	636	756	N/A
9/30/2021	3,135	757	663	765	N/A
6/30/2021	3,047	728	694	770	N/A
3/31/2021	2,858	674	666	745	N/A
12/31/2020	2,707	582	540	648	N/A
9/30/2020	2,591	497	445	585	N/A
6/30/2020	2,475	460	366	524	N/A
3/31/2020	2,457	437	286	453	N/A
12/31/2019	2,407	428	304	459	N/A
9/30/2019	2,351	423	290	439	N/A
6/30/2019	2,291	407	274	418	N/A
3/31/2019	2,252	390	262	400	N/A
12/31/2018	2,213	377	277	400	N/A
9/30/2018	2,170	330	280	386	N/A
6/30/2018	2,117	307	296	386	N/A
3/31/2018	2,045	284	300	377	N/A
12/31/2017	1,969	263	N/A	373	N/A
9/30/2017	1,906	277	N/A	353	N/A
6/30/2017	1,862	263	N/A	343	N/A
3/31/2017	1,820	245	N/A	343	N/A
12/31/2016	1,775	222	N/A	339	N/A
9/30/2016	1,732	214	N/A	312	N/A
6/30/2016	1,690	202	N/A	289	N/A
3/31/2016	1,637	192	N/A	258	N/A
12/31/2015	1,602	192	N/A	222	N/A
9/30/2015	1,554	174	N/A	170	N/A
6/30/2015	1,531	182	N/A	186	N/A
3/31/2015	1,508	182	N/A	188	N/A
12/31/2014	1,486	182	N/A	236	N/A
9/30/2014	1,488	199	N/A	274	N/A
6/30/2014	1,443	193	N/A	259	N/A
3/31/2014	1,405	190	N/A	258	N/A
12/31/2013	1,377	188	N/A	246	N/A
9/30/2013	1,343	188	N/A	250	N/A
6/30/2013	1,320	185	N/A	246	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IDXX * 의 연간 예상 수익 증가율( 9.9% )이 saving rate( 7.8% 보다 높습니다. ).

수익 vs 시장: IDXX * 의 연간 수익( 9.9% ) MX 시장( 11.2% 보다 느리게 성장할 것으로 예상됩니다. 11.2% 연간).

고성장 수익: IDXX * 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: IDXX * 의 수익(연간 8.7% ) MX 시장( 7.1% 보다 빠르게 성장할 것으로 예상됩니다. 7.1% 연간).

고성장 수익: IDXX * 의 수익(연간 8.7% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IDXX * 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 35.6 %)

IDEXX Laboratories 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

Recent updates

Independent Director recently sold Mex$1.8m worth of stock

IDEXX Laboratories, Inc. to Report Q2, 2024 Results on Aug 06, 2024

IDEXX Laboratories, Inc., Annual General Meeting, May 06, 2024

First quarter 2024 earnings released: EPS: US$2.84 (vs US$2.58 in 1Q 2023)

Idexx Laboratories, Inc. Revises Earnings Guidance for 2024

Insufficient new directors

Idexx Launches Vellotm, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

IDEXX Laboratories, Inc. to Report Q1, 2024 Results on May 02, 2024

IDEXX Laboratories, Inc. Provides Financial Guidance for 2024

Full year 2023 earnings released: EPS: US$10.17 (vs US$8.12 in FY 2022)

Insufficient new directors

IDEXX Laboratories, Inc. Announces Retirement of James F. Polewaczyk, Executive Vice President and Chief Commercial Officer, Effective April 1, 2024

Insufficient new directors

IDEXX Laboratories, Inc. Expands Snap Platform with Leish 4Dx Test to Support Veterinarians Globally in Diagnosing Vector-Borne Diseases

IDEXX Laboratories, Inc. Provides Financial Guidance for 2023

Third quarter 2023 earnings released: EPS: US$2.55 (vs US$2.17 in 3Q 2022)

IDEXX Laboratories, Inc. to Report Q4, 2023 Results on Feb 05, 2024

Executive VP & Chief Commercial Officer recently sold Mex$52m worth of stock

IDEXX Laboratories, Inc. to Report Q3, 2023 Results on Nov 01, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Insufficient new directors

IDEXX Laboratories, Inc. Announces the Election of Irene Chang Britt as an Independent Class I Director and as an Independent Member of Audit Committee and Compensation and Talent Committee

Insufficient new directors

IDEXX Laboratories, Inc. Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry's Most Comprehensive Renal Testing Portfolio

Insufficient new directors

Independent Director recently sold Mex$17m worth of stock

First quarter 2023 earnings released: EPS: US$2.58 (vs US$2.30 in 1Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q1, 2023 Results on May 02, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Insufficient new directors

IDEXX Laboratories, Inc. to Report Q4, 2022 Results on Feb 06, 2023

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Full Year 2022

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment deteriorated over the past week

IDEXX Laboratories, Inc. to Report Q2, 2022 Results on Aug 02, 2022

First quarter 2022 earnings released: EPS: US$2.30 (vs US$2.39 in 1Q 2021)

IDEXX Laboratories, Inc., Annual General Meeting, May 11, 2022

IDEXX Laboratories, Inc. to Report Q1, 2022 Results on May 04, 2022

Senior Advisor & Director recently sold Mex$2.6m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IDEXX Laboratories, Inc. Provides Earnings Guidance for the Year 2022

IDEXX Laboratories, Inc. Announces Series of Product and Service Enhancements That Enable Veterinary Practices to Be More Efficient While Managing Increasing Patient Volumes

President recently sold Mex$81m worth of stock

Insider recently sold Mex$142m worth of stock

IDEXX Laboratories, Inc.(NasdaqGS:IDXX) dropped from Russell 1000 Dynamic Index

IDEXX Laboratories, Inc. (NasdaqGS:IDXX) acquired ezyVet.

Independent Director has left the company

Senior Advisor & Director recently sold Mex$5.5m worth of stock

First quarter 2021 earnings released: EPS US$2.39 (vs US$1.31 in 1Q 2020)

IDEXX Laboratories, Inc. Raises Earnings Guidance for 2021

Independent Director recently sold Mex$3.3m worth of stock

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견